Previous studies on molecular recognition of uranyl-DCP (dicarboxy-phenanthroline chelator) compound by two distinct monoclonal antibodies (Mabs U04S and U08S) clearly showed the presence of a biphasic shape in Bell-Evans' plots and an accentuated difference in slopes at the high loading rates.
The C-domain of ACE is followed by a stalk region of ∼32 amino acids which is cleaved by a still unidentified ACE sheddase that is inhibitable by metal ion chelators, compound 3 (5) and TAPI-1 (TNF-α protease inhibitor-1) (6).
Chelating drugs and chelator metal complexes are used for the prevention, diagnosis and treatment of cancer and chelating compounds with high affinity for iron or copper have been suggested as potential anti-tumor agents [ 7].
First, it should be noted that, unlike the iron-chelating compounds studied previously (Sterba et al, 2006, 2007; Popelova et al, 2008), the putative active metabolite of DEX (ADR-925) is far from being a selective iron chelator.
Based on a multimodal drug design paradigm, we have synthesized a multifunctional non-toxic, brain permeable iron chelating compound, M30, possessing the neuroprotective N-propargyl moiety of the anti-Parkinsonian drug, monoamine oxidase (MAO -B inhibitor, rasagiline and the antioxidant-iron chelator MAO -B of an 8-hydroxyquinhibitorerasagilinef the iron chelandr, VK28.
Fu et al., revealed that cross-linking can be inhibited in the presence of metal chelators, sulfhydryl compounds, antioxidants and AG as they can uncouple glycation from subsequent cross-linking reactions [ 16].
Using the tetraamine chelator, four further agonist compounds were developed: [N40,Pro,Tyr]BN and its Nle-substituted analogue (Demobesin 3 and 4) as well as two truncated BN analogues, [(N4-Bzdig)]BN(7 14) and its Nle-substituted analogue, using a benzylaminodiglycolic acid spacer between the chelator and the receptor-binding sequence (Demobesin 5 and 6) [ 73].
Several other labeling methods [16, 17] and chelators [18 21] for labeling compounds with 68Ga are described with more efficient labeling yields and faster labeling kinetics.
In this study, we have conjugated DFOB to derivatives of adamantane or the clinical iron chelator deferasirox to produce lipophilic compounds designed to increase the bioavailability of DFOB to brain cells.
We show that these compounds are intracellular chelators with the capacity to exist in two isomeric states.
